GRACEcastUC-038_Lung_Managing Acq. Resistance to EGFR Therapy (and Probably Crizotinib, Too) Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC
Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, outlines how useful cell-free DNA sequencing will be in the Association Between Plasma Genotyping and Outcomes of
Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC Geoffrey R. Oxnard, MD, assistant professor of Medicine, Dana-Farber Cancer Center, Harvard Medical School, discusses a study Geoffrey Oxnard, MD, a thoracic oncologist at Dana-Farber Cancer Institute, led research showing Liquid Biopsy can accurately
Cancer detecting and locating: cell-free DNA Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, Dana-Farber Cancer
Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer Liquid Biopsy: Differences Among Technologies Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, explains how targeted bisulfite sequencing of plasma cell-free
Geoffrey R. Oxnard. Employment: Foundation Medicine. Stock and Other Authors. Affiliations Expand All. Geoffrey R. Oxnard, MD https://orcid. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer Is It Possible to Test Lung Tumors Without Doing a Biopsy?
CCGA: plasma cfDNA lung cancer screening Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses Clinical Applications for NSCLC Liquid Biopsy
Dr. Geoffrey Oxnard from Harvard Medical School talks about EGFR inhibitors and mutations, filmed at IASLC in February 2014. Dr. Oxnard, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, explains how genomic
How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow? Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the choices for genetic testing in metastatic non–small cell lung cancer
Liquid Biopsy for NSCLC: Emerging Developments Widespread Mutation Testing for NSCLC
Cell-free DNA for multi-cancer detection Sandip Patel, MD, and Geoffrey R. Oxnard, MD, explain the strengths and limitations of plasma-based genetic profiling for
TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer Geoff Oxnard. BlossomHill Therapeutics, Inc. The University of Chicago Pritzker School of Medicine. Cambridge, Massachusetts, United
Geoffrey R. Oxnard, MD Analysis of tumor DNA has transformed cancer care, allowing researchers to identify unique vulnerabilities within some cancers and Where Do We Go Next with EGFR Inhibitors?
Upfront EGFR-Targeted Therapy for NSCLC Impact of COVID-19 on scientific research and treating patients
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the nuances of non–small cell lung cancer mutation testing using Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer
Patient from Hell Ep 62: Transforming Lung Cancer Treatment using Precision Medicine Foundation Medicine Appoints Dr. Geoffrey Oxnard as Vice Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the downfalls of the use of cell-free DNA in the
Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the Targeted Treatment for Lung Cancer After Progression
Geoffrey Oxnard, MD, of Dana-Farber's Lowe Center for Thoracic Oncology, discuss how a simple blood test may be able to help Geoffrey R Oxnard Geoffrey R. Oxnard, Ryan S. Alden, Cloud P. Paweletz, and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston; Kenneth S.
How Does Liquid Biopsy Work? How a Blood Test Can Find Genetic Abnormalities in Lung Cancer | Dana-Farber Cancer Institute
Final Thoughts Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib
May 18th Lung Webinar on Molecular Diagnostics in #NSCLC liquid and Tissue NGS. Dr. Geoffrey Oxnard from Harvard Medical School talks about driver mutation, filmed at IASLC in February 2014. Oncology. Geoff Oxnard MD (@geoff_oxnard) - Posts - Drug & diagnostic developer | Thoracic oncology, Boston Medical Center | Husband, father of 4, split.
Geoffrey Oxnard, MD, of Dana-Farber's Lowe Center for Thoracic Oncology, shares his tips for how lung cancer patients can make Advice for Lung Cancer Patients | Dana-Farber Cancer Institute Germline EGFR Mutations and Familial Lung Cancer | Journal of
Sandip Patel, MD, and Geoffrey R. Oxnard, MD, explains how to interpret the results of liquid biopsy results for metastatic Cell-free DNA sequencing in the clinical setting Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, highlights the impact of COVID-19 on research studies and
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the current recommendations for genetic testing in patients with Cell-free DNA liquid biopsy in lung cancer At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey Oxnard, MD, from Dana-Farber Cancer
In this episode, Dr. Geoff Oxnard, a thoracic oncologist, discusses his career journey into oncology and shares insights from his Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study Cell-free (cf)DNA analysis is frequently used in lung cancer to identify therapeutic targets, but there has also been recent interest
Four change makers are being awarded for the impact they have made in the fight against cancer. In their first year, the Cancer Liquid Biopsy and Next-Generation Sequencing
Dr. Geoffrey Oxnard describes a study that aims to identify non-smoking lung cancer patients who have a rare EGFR mutation, TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer
Dr. Oxnard Discusses RET Fusions in NSCLC Geoffrey R. Oxnard, MD, and Sandip Patel, MD, describe the value of large panel genetic profiling for metastatic non–small cell
Geoffrey R. Oxnard, MD | Boston Medical Center MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are In this segment, Mark A. Socinski, MD; Mary Jo Fidler, MD; Roy S. Herbst, MD, PhD; and Geoffrey R. Oxnard, MD, discuss options
About · Contact. 617.638.7524 · Primary Location. 830 Harrison Ave Moakley 3. Boston, MA 02118. Administrative Title. Associate Professor of Hematology and Interpretation of NSCLC Plasma Genotyping Results Subscribe to the Bio-Rad channel: Geoffrey R. Oxnard,
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD, echo the sentiment How to Understand EGFR T790M Mutations | Dana-Farber Cancer Institute Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss current unmet needs and emerging developments in the use of plasma
Dr. Oxnard, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, considers whether lorlatinib Geoffrey R. Oxnard, MD | Damon Runyon Cancer Research Dr. Geoffrey R. Oxnard Treating Patients Who Have Become Resistant to EGFR-Inhibitors
Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Awad, Geoffrey R. Oxnard, David M. Jackman, Jennifer C. Heng, Suzanne E. Dahlberg, Pasi A. Jänne, and Peter S. Hammerman, Dana-
GRACEcastUC-022_Lung_What is an Inherited T790M EGFR Mutation, and What Does It Mean? The Pitfalls of cell-free DNA sequencing At the American Society of Clinical Oncology (ASCO) 2012, Geoff Oxnard, MD, discusses how decisions are made about if and
Sandip Patel, MD, and Geoffrey R. Oxnard, MD, discuss differences among platforms for genetic profiling of metastatic non–small Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of liquid biopsy for identifying resistance Germline EGFR Mutations and Familial Lung Cancer
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the use of plasma-based genetic profiling of EGFR and ALK resistance Geoff Oxnard MD (@geoff_oxnard) / Posts / X
Liquid Biopsy study | Dana-Farber Cancer Institute Geoffrey R. Oxnard, MD - Google Scholar
Plasma Testing for NSCLC EGFR & ALK Mutations Geoff Oxnard - BlossomHill Therapeutics, Inc. | LinkedIn Geoffrey R. Oxnard as vice president, global medical lead for the Company's liquid biopsy portfolio, effective immediately. He joins
The liquid biopsy test is approved to identify patients who may benefit from treatment with specific FDA-approved targeted Is Lung Cancer Hereditary? | Dana-Farber Cancer Institute Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology,
How Liquid Biopsies Help Understanding of Resistance to Chemotherapy Genetic Testing for NSCLC Geoffrey R. Oxnard, MD, on the Approval of the FoundationOne Liquid CDx
Acquired Resistance to Osimertinib in T790M-Positive NSCLC Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing
Lung Cancer - interview with Geoff Oxnard, MD, at ASCO 2012 Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will Lung Cancer Webinar held on May 18, moderated by Hatim Husain, MD UCSD and discussants Joel Neal, MD, Stanford and
Sandip Patel, MD, and Geoffrey R. Oxnard, MD, discuss increased adoption for plasma genotyping in non–small cell lung cancer Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the recent publication he co-authored in the Annals of Which NSCLC Patients to Recommend Repeat Biopsies with Insufficient Tissue for Molecular Testing
The Role for Liquid Biopsy in NSCLC Geoffrey Oxnard | Medicine Geoffrey Oxnard, MD, discusses whether lung cancer can be passed down in families, and whether there is are familial risks other
Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, GRACEcastUC 124 Lung_Dr. Oxnard on Repeat Biopsy with Acquired Resistance Targeted Therapy Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small
Recognizing People Making a Difference in Fighting Cancer Dr. Geoffrey Oxnard from Harvard Medical School talks about EGFR treatment decisions, filmed at IASLC in February 2014. Dr. Oxnard, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, on whether the overall
Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School.